Literature DB >> 31637971

Intensive Blood Pressure Treatment Reduced Stroke Risk in Patients With Albuminuria in the SPRINT Trial.

Lia Leitão1, Ricardo Soares-Dos-Reis2,3,4, João Sérgio Neves5,6, Rute Baeta Baptista7,8, Miguel Bigotte Vieira9, Finnian R Mc Causland10.   

Abstract

Background and Purpose- Albuminuria is associated with stroke risk among individuals with diabetes. However, the association of albuminuria with incident stroke among nondiabetic patients is less clear. Methods- We performed a post hoc analysis of the SPRINT (Systolic Blood Pressure Intervention Trial), which examined the effect of higher versus lower intensity blood pressure management on mortality in 8913 participants without diabetes. We fit unadjusted and adjusted Cox proportional hazards models to estimate the association of baseline albuminuria (urinary albumin-to-creatinine ratio ≥30 mg/g versus<30 mg/g) with stroke risk. We also assessed effect modification according to treatment arms. Results- Mean age was 68±9 years, 35% were female, and 30% were black. Median follow-up was 3.2 years, and 19% patients had baseline albuminuria. Incident stroke occurred in 129 individuals during follow-up. Albuminuria was associated with increased stroke risk (unadjusted hazard ratio, 2.24; 95% CI, 1.55-3.23; adjusted hazard ratio 1.73; 95% CI, 1.17-2.56). The association of albuminuria with incident stroke differed according to the randomized treatment arm (P interaction=0.03). In the intensive treatment arm, the association of albuminuria and stroke was nonsignificant (unadjusted hazard ratio, 1.25; 95% CI, 0.69-2.28), whereas, in the standard treatment arm, it was significant (unadjusted hazard ratio, 3.44; 95% CI, 2.11-5.61). Conclusions- In a post hoc analysis of SPRINT, baseline albuminuria (versus not) was associated with a higher risk of incident stroke, but this relationship appeared to be restricted to those in the standard treatment arm. Further studies are required to conclusively determine if reduction of albuminuria in itself is beneficial in reducing stroke risk. Clinical Trial Registration- URL: https://www.clinicaltrials.gov. Unique identifier: NCT01206062.

Entities:  

Keywords:  albuminuria; blood pressure; diabetes mellitus; hypertension; stroke

Year:  2019        PMID: 31637971      PMCID: PMC6878195          DOI: 10.1161/STROKEAHA.119.026316

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  9 in total

1.  Impact of microalbuminuria on incident stroke: a meta-analysis.

Authors:  Meng Lee; Jeffrey L Saver; Kuo-Hsuan Chang; Hung-Wei Liao; Shen-Chih Chang; Bruce Ovbiagele
Journal:  Stroke       Date:  2010-10-07       Impact factor: 7.914

2.  Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

Authors:  Faramarz Ismail-Beigi; Timothy Craven; Mary Ann Banerji; Jan Basile; Jorge Calles; Robert M Cohen; Robert Cuddihy; William C Cushman; Saul Genuth; Richard H Grimm; Bruce P Hamilton; Byron Hoogwerf; Diane Karl; Lois Katz; Armand Krikorian; Patrick O'Connor; Rodica Pop-Busui; Ulrich Schubart; Debra Simmons; Harris Taylor; Abraham Thomas; Daniel Weiss; Irene Hramiak
Journal:  Lancet       Date:  2010-06-30       Impact factor: 79.321

3.  Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria:Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT).

Authors:  Frank P Brouwers; Folkert W Asselbergs; Hans L Hillege; Rudolf A de Boer; Ron T Gansevoort; Dirk J van Veldhuisen; Wiek H van Gilst
Journal:  Am Heart J       Date:  2011-05-11       Impact factor: 4.749

4.  Association of Ambulatory Blood Pressure Monitoring parameters with the Framingham Stroke Risk Profile.

Authors:  Georgios Tsivgoulis; Maria Pikilidou; Aristeidis H Katsanos; Kimon Stamatelopoulos; Fotios Michas; Aikaterini Lykka; Christina Zompola; Angeliki Filippatou; Efstathios Boviatsis; Konstantinos Voumvourakis; Nikolaos Zakopoulos; Efstathios Manios
Journal:  J Neurol Sci       Date:  2017-07-05       Impact factor: 3.181

5.  Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT).

Authors:  Daniel E Weiner; Sarah A Gaussoin; John Nord; Alexander P Auchus; Gordon J Chelune; Michel Chonchol; Laura Coker; William E Haley; Anthony A Killeen; Paul L Kimmel; Alan J Lerner; Suzanne Oparil; Mohammad G Saklayen; Yelena M Slinin; Clinton B Wright; Jeff D Williamson; Manjula Kurella Tamura
Journal:  Am J Kidney Dis       Date:  2017-06-09       Impact factor: 8.860

Review 6.  Blood Pressure Reduction and Secondary Stroke Prevention: A Systematic Review and Metaregression Analysis of Randomized Clinical Trials.

Authors:  Aristeidis H Katsanos; Angeliki Filippatou; Efstathios Manios; Spyridon Deftereos; John Parissis; Alexandra Frogoudaki; Agathi-Rosa Vrettou; Ignatios Ikonomidis; Maria Pikilidou; Odysseas Kargiotis; Konstantinos Voumvourakis; Anne W Alexandrov; Andrei V Alexandrov; Georgios Tsivgoulis
Journal:  Hypertension       Date:  2016-10-31       Impact factor: 10.190

7.  Association of kidney disease measures with ischemic versus hemorrhagic strokes: pooled analyses of 4 prospective community-based cohorts.

Authors:  Bakhtawar K Mahmoodi; Hiroshi Yatsuya; Kunihiro Matsushita; Yinying Sang; Rebecca F Gottesman; Brad C Astor; Mark Woodward; W T Longstreth; Bruce M Psaty; Michael G Shlipak; Aaron R Folsom; Ron T Gansevoort; Josef Coresh
Journal:  Stroke       Date:  2014-05-29       Impact factor: 7.914

8.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

Authors:  Jackson T Wright; Jeff D Williamson; Paul K Whelton; Joni K Snyder; Kaycee M Sink; Michael V Rocco; David M Reboussin; Mahboob Rahman; Suzanne Oparil; Cora E Lewis; Paul L Kimmel; Karen C Johnson; David C Goff; Lawrence J Fine; Jeffrey A Cutler; William C Cushman; Alfred K Cheung; Walter T Ambrosius
Journal:  N Engl J Med       Date:  2015-11-09       Impact factor: 91.245

9.  Chronic kidney disease and poor outcomes in ischemic stroke: is impaired cerebral autoregulation the missing link?

Authors:  Pedro Castro; Elsa Azevedo; Isabel Rocha; Farzaneh Sorond; Jorge M Serrador
Journal:  BMC Neurol       Date:  2018-03-02       Impact factor: 2.474

  9 in total
  5 in total

1.  Predictive Factors for Target Organ Injuries in Hypertensive Individuals.

Authors:  Manoel Paz Landim; Luciana Neves Cosenso-Martin; Aleandra Polegati Santos; Jessica Rodrigues Roma Uyemura; Leticia Barufi Fernandes; Valquiria da Silva Lopes; Juan Carlos Yugar-Toledo; Jose Fernando Vilela-Martin
Journal:  Integr Blood Press Control       Date:  2021-08-14

Review 2.  Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence?

Authors:  Boris Bikbov; Maria José Soler; Vesna Pešić; Giovambattista Capasso; Robert Unwin; Matthias Endres; Giuseppe Remuzzi; Norberto Perico; Ron Gansevoort; Francesco Mattace-Raso; Annette Bruchfeld; Andreja Figurek; Gaye Hafez
Journal:  Nephrol Dial Transplant       Date:  2021-12-28       Impact factor: 5.992

3.  Evaluation of the association between admission systolic blood pressure and the choice of initial antiplatelet therapy for minor ischemic stroke in real-world.

Authors:  Tingting Liu; Yongle Wang; Xiaoyuan Niu; Yanan Li; Kaili Zhang; Haimei Fan; Jing Ren; Juan Li; Liansheng Ma; Xinyi Li; Xuemei Wu
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-03-16       Impact factor: 3.738

Review 4.  Time to benefit for stroke reduction after blood pressure treatment in older adults: A meta-analysis.

Authors:  Vanessa S Ho; Irena S Cenzer; Brian T Nguyen; Sei J Lee
Journal:  J Am Geriatr Soc       Date:  2022-02-09       Impact factor: 7.538

5.  Factors affecting physician decision-making regarding antiplatelet therapy in minor ischemic stroke.

Authors:  Tingting Liu; Yanan Li; Xiaoyuan Niu; Yongle Wang; Kaili Zhang; Haimei Fan; Jing Ren; Juan Li; Yalan Fang; Xinyi Li; Xuemei Wu
Journal:  Front Neurol       Date:  2022-09-01       Impact factor: 4.086

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.